New tuberculosis drug development: Targeting the shikimate pathway

Senta M. Kapnick, Ying Zhang

Research output: Contribution to journalReview articlepeer-review


Background: Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, yet no new drugs have been developed in the last 40 years. Objective: The exceedingly lengthy TB chemotherapy and the increasing emergence of drug resistance complicated by HIV co-infection call for the development of new TB drugs. These problems are further compounded by a poor understanding of the biology of persister bacteria. Methods: New molecular tools have offered insights into potential new drug targets, particularly the enzymes of the shikimate pathway, which is the focus of this review. Results/conclusion: Shikimate pathway enzymes, especially shikimate kinase, may offer attractive targets for new TB drug and vaccine development.

Original languageEnglish (US)
Pages (from-to)565-577
Number of pages13
JournalExpert Opinion on Drug Discovery
Issue number5
StatePublished - May 2008


  • Drug development
  • Mycobacterium tuberculosis
  • Shikimate kinase
  • Shikimate pathway

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint Dive into the research topics of 'New tuberculosis drug development: Targeting the shikimate pathway'. Together they form a unique fingerprint.

Cite this